

Contact: Susan Levin
Tel: (631) 444-6181
Email: slevin@viatronix.com

FOR IMMEDIATE RELEASE

**Viatronix V3D-Colon utilized in “another” important clinical trial –
the ACRIN Trial**

STONY BROOK, NY September 18th, 2008-- Stony Brook based Viatronix Incorporated (www.viatronix.com), a leading innovator and developer of 3D imaging software announced today that with the publication of a new study in the New England Journal of Medicine, titled “Accuracy of CT Colonography for Detection of Large Adenomas and Cancers” the industry has seemingly placed the last piece of the puzzle to move towards CT Colonography (CTC) as a reimbursable screening method for colorectal cancer. The study utilized the Viatronix V3D-Colon platform along with other workstations.

The study, conducted by the American College of Radiology Imaging Network (ACRIN) at 15 centers across the U.S., published its results in the September 18th issue of the New England Journal of Medicine (NEJM). The study compared primary CTC screening with Optical Colonoscopy (OC) screening in 2,531 adults and found that primary CTC when used to screen asymptomatic patients has 90% sensitivity for polyps 10mm or larger.

“We believe this multi-center study further confirms CTC as a mainstream screening tool for colorectal cancer and reinforces the previous studies, such as the landmark DOD trial published in the December 2003 NEJM that exclusively used our V3D-Colon software which actually attained a much higher accuracy” said Viatronix President, Zaffar Hayat.

The Viatronix V3D-Colon has been used in the following clinical trials:

- 1. "Computed Tomographic Virtual Colonoscopy to Screen for Colorectal neoplasia in Asymptomatic Adults",** Perry J. Pickhardt, M.D., J. Richard Choi, Sc.D., M.D., Inku Hwang, M.D., James A. Butler, M.D., Michael L. Puckett, M.D., Hans A. Hildebrandt, M.D., Roy K. Wong, M.D., Pamela A. Nugent, M.D., Pauline A. Mysliwiec, M.D., M.P.H., and William R. Schindler, D.O., NEJM, December 2003 issue (Vol. 349, No. 23)

Exclusively utilized the Viatronix V3D-Colon Platform... *The trials' results proved that VC, when performed using Viatronix's V3D-Colon software, provided results equal to OC, and in some instances even better than OC for colon cancer screening. In addition, results concluded that VC performed using V3D-Colon may detect abnormalities imbedded in the colon wall and in adjacent areas outside of the colon, areas that cannot be seen using OC. In adenomatous polyps ≥ 10 mm in size the VC sensitivity per patient was 93.8% and the OC sensitivity per patient was 87.5%. In adenomatous polyps ≥ 8 mm in size the VC sensitivity per patient was 93.9% and the OC sensitivity per patient was 89.5%.*

- 2. "Screening for Colorectal Neoplasia with CT Colonography: Initial Experience from the 1st Year of Coverage by Third-Party Payers",** Perry J. Pickhardt, MD, Andrew J. Taylor, MD, David H. Kim, MD, Mark Reichelderfer, MD, Deepak V. Gopal, MD, and Patrick R. Pfau, MD, *Radiology*, 2006. 0:24120520073

Exclusively utilized the Viatronix V3D-Colon Platform... *Results unequivocally advocated that the V3D-Colon again showed a high degree of sensitivity, and the results showed that Viatronix's VC system is the only VC product proven for the second time to have the highest sensitivity. In all polyps ≥ 6 mm the positive predictive value per patient was 91.5%. In all polyps ≥ 6 mm the positive predictive value per polyp was 88.5%.*

- 3. "Virtual vs. optical colonoscopy in symptomatic gastroenterology out-patients: the case for virtual imaging followed by targeted diagnostic or therapeutic colonoscopy",** M.Bose, J.Bell, L.Jackson, P.Casey, J.Saunders, O.Epstein Volume 26 Issue 5 Page 727-736, *Alimentary Pharmacology & Therapeutics*, September 2007

Exclusively utilized the Viatronix V3D-Colon Platform... *In a 100-patient independent clinical trial, conducted at the Royal Free Hospital in UK, V3D-Colon was found to have the high sensitivity recorded in the NEJM multi-center study. Per patient VC Specificity ≥ 6 mm – VC 100% / OC 91% (from 90 patients).*

- 4. "CT Colonography versus Colonoscopy for the Detection of Advanced Neoplasia",** David H. Kim, M.D., Perry J. Pickhardt, M.D., Andrew J. Taylor, M.D., Winifred K. Leung, M.D., Thomas C. Winter, M.D., J. Louis Hinshaw, M.D., Deepak V. Gopal, M.D., Mark Reichelderfer, M.D., Richard H. Hsu, M.D., and Patrick R. Pfau, M.D., *NEJM*, October 4, 2007, (Vol. 357, No. 14)

Exclusively utilized the Viatronix V3D-Colon Platform... *The results compared primary CTC screening in 3,120 adults with primary OC screening in 3,163 adults and found that primary CTC and OC for colon cancer screening provide similar detection rates for advanced neoplasia. Total advanced neoplasms found through CTC screening of 3,120 patients was 123. Total advanced neoplasms found through OC screening of 3,163 patients was 121.*

- 5. "Accuracy of CT Colonography for Detection of Large Adenomas and Cancers",** C. Daniel Johnson, M.D., M.M.M., Mei-Hsiu Chen, Ph.D., Alicia Y. Toledano, Sc.D., Jay P. Heiken, M.D., Abraham Dachman, M.D., Mark D. Kuo, M.D., Christine O. Menias, M.D., Betina Siewert, M.D., Jugesh I. Cheema, M.D., Richard G. Obregon, M.D., Jeff L. Fidler, M.D., Peter Zimmerman, M.D., Karen M. Horton, M.D., Kevin Coakley, M.D., Revathy B. Iyer, M.D., Amy K. Hara, M.D., Robert A. Halvorsen, Jr., M.D., Giovanna Casola, M.D., Judy Yee, M.D., Benjamin A. Herman, S.M., Lawrence J. Burgart, M.D., and Paul J. Limburg, M.D., M.P.H., *NEJM*, September 18, 2008, (Volume 359, No. 12)

Utilizing multiple CT Colonography workstations including the Viatronix V3D-Colon platform. *In this study of asymptomatic adults, CT colonographic screening identified 90% of subjects with adenomas or cancers measuring 10 mm or more in diameter. These findings augment published data on the role of CT colonography in screening patients with an average risk of colorectal cancer. Complete data were available for 2,531 participants (97%). For large adenomas and cancers, the mean (\pm SE) per-patient estimates of the sensitivity, specificity, positive and negative predictive values, and area under the receiver-operating-characteristic curve for CT colonography were 0.90 ± 0.03 , 0.86 ± 0.02 , 0.23 ± 0.02 , $0.99\pm <0.01$, and 0.89 ± 0.02 , respectively. The sensitivity of 0.90 (i.e., 90%) indicates that CT colonography failed to detect a lesion measuring 10 mm or more in diameter in 10% of patients. The per-polyp sensitivity for large adenomas or cancers was 0.84 ± 0.04 . The per-patient sensitivity for detecting adenomas that were 6 mm or more in diameter was 0.78.*

About Viatronix

Viatronix is a leading innovator and developer of 2D/3D medical imaging and diagnostic software. Our software enables physicians to interactively view vital organs and anatomical structures within the human body from data acquired by standard medical imaging equipment in minimally or non-invasive methods. The 2D digital data acquired from imaging devices is automatically post processed using the company's proprietary software techniques and provides 3D diagnostic quality images for the physician. The company's first product, V3D-Colon for "virtual colonoscopy" allows physicians to interactively view the colon reconstructed from a CT scan, providing visualization of the entire colon wall which includes polyps and other lesions. The company's V3D-Explorer offers a robust and user-friendly workstation platform that views and reconstructs data in 2D/3D for virtually any organ in the body. V3D-Calcium Scoring aids physicians in determining the amount of calcified plaque accumulation in the coronary arteries. V3D-Vascular is breakthrough software that permits rapid segmentation and visualization of complex arterial structures using 3D volume rendering, maximum intensity projection and simulated x-ray views. Viatronix, through application of the V3D technology, is developing additional innovative products that will be useful in early detection of other diseases, treatment planning, intervention, and follow-up evaluation. Viatronix, Inc. is located in Stony Brook, NY. For further information, call toll free 1-866-887-4636 or log on to: www.viatronix.com

Contacts:

Viatronix

Susan Levin

E-mail: slevin@viatronix.com

Phone: (631) 444-6181

Fax: (631) 444-9701

#